FDAnews
www.fdanews.com/articles/70900-xdx-launches-test-to-enable-better-management

XDx Launches Test to Enable Better Management

April 8, 2005

XDx, a molecular diagnostics company, announced the launch of an innovative test for the management of heart transplant patients. AlloMap molecular expression testing is a non-invasive method to monitor a patient's immune system that, unlike conventional methods, identifies the risk of tissue damage and rejection before it occurs and may enable physicians to proactively manage immunosuppressive medications.

Yahoo News (http://biz.yahoo.com/prnews/050406/sfw044.html?.v=6)